Reviewer’s report
Title: 
The inhibitory effect of curcumin via fascin suppression through
JAK/STAT3 pathway on metastasis and recurrence of ovary cancer cells.
Version: 
0 
Date: 
24 Aug 2020
Reviewer's report:
Dear authors, 
Firstly, I'd like to congratulate you for the efforts.
The study proposes to evaluate the effect of curcumin on the expression of fascin
in an ovarian cancer cell line. It is a well-designed study, with a plausible
hypothesis, and quite interesting. The methods were adequate and the results are
well presented. The conclusions are relevant. Perhaps it is interesting to discuss a
little more in the introduction some existing information about the potential
blockage of metastasis through the inhibition of fascination in ovarian cancer
(e.g. doi: 10.1016 / j.ygyno.2019.01.020).
Major:
I think the discussion could be improved. There is a great deal of information
about the possible effects of curcumin and its derivatives as an anticancer agent.
I suggest two articles to assist the author: (A review of curcumin and its
derivatives as anticancer agents by Tomeh et al, published i nInt J Mol Sci, 2019,
doi: 10.3390 / ijms20051033) and (Curcumin and Cancer by Giordano and
Tommoraro, published in Nutrients, 2019, doi: 10.3390 / nu11102376);
Another point that I find very interesting is to discuss and point out the clinical
trials that are being conducted using curcumin.
Still in the discussion section: I suggest starting the discussion with a synthesis
of the results. Thus, it can become more attractive and more informative to the
reader. 
The first three/four paragraphs of the discussion are more appropriate to
the introduction.
In the fifth paragraph, the author repeats the objective of the study. I don't think
it's necessary. At this point he presents a summary of his result. In my opinion,
this is where the discussion really begins.
Minor:
1. Although widely used, I suggest avoiding abbreviations in the abstract, e.g.,
MTS
2. I don't see the need to quote the abbreviation VEGFR in line 15 of the
introduction page because it was used only once.
Figures
1. Please, indicate the statistical significance in graphics. Inform in "notes" the
differences on times between 1A and 1B.
Publons Reviewer Recognition
. Springer Nature can send verification of this
review directly to Publons (a subsidiary of Clarivate Analytics). If you would
like to take advantage of this service, please click on the “Yes” option below.
Your name, email address, title of the reviewed manuscript, name of the journal,
and date of your review submission (the “Review Data”) will then be transmitted
to Publons upon publication of the manuscript. If you have already registered at
Publons, they will notify you of the receipt of this review and update your profile
as per your settings and their policy. If you are not registered with Publons, you
will receive an email from them asking you to register in order for them to be
able to recognize your review on your new profile page. Publons may use the
Review Data to generate derivative metadata for the benefit of Publons and you
as a reviewer, carefully considering the sensitivity of such information. For
example, Publons may verify your record as a reviewer by updating your profile
published on its webservice if you have registered for such service or help
editors to identify candidate reviewers. Please find the details of processing in
Publons’ privacy policy 
https://publons.com/about/terms
Yes
Declaration of competing interests
Please complete a declaration of competing interests, considering the following
questions:
1
. 
Have you in the past five years received reimbursements, fees, funding, or
salary from an organisation that may in any way gain or lose financially
from the publication of this manuscript, either now or in the future?
2
. 
Do you hold any stocks or shares in an organisation that may in any way
gain or lose financially from the publication of this manuscript, either now
or in the future?
3
. 
Do you hold or are you currently applying for any patents relating to the
content of the manuscript?
4
. 
Have you received reimbursements, fees, funding, or salary from an
organization that holds or has applied for patents relating to the content of
the manuscript?
5
. 
Do you have any other financial competing interests?
6
. 
Do you have any non-financial competing interests in relation to this
paper?
If you can answer no to all of the above, write 'I declare that I have no competing
interests' below. If your reply is yes to any, please give details below.
I declare that I have no competing interests
Reviewer Publication Consent.
 I agree for my report to be made available
under an Open Access Creative Commons CC-BY License (
http://creativecommons.org/licenses/by/4.0
) if this manuscript is accepted for
publication. Any comments that I do not wish to be included in the published
report have been included as confidential comments to the editor, which will not
be published.
If you are not happy for us to publish this report, please contact the editorial
office before completing the review.
If you wish, you can include your name in your published report. Please note
you must decide whether to include your name at the start of the process and
confirm this decision whenever prompted. If you change your decision later, we
will not be able to publish your name.
I agree to the terms of the CC-BY 4.0 license; please 
do not
 publish my name
with my report. (default)
Is the study design appropriate to answer the research question (including the use
of appropriate controls), and are the conclusions supported by the evidence
presented?
Yes
Are the methods sufficiently described to allow the study to be repeated?
Yes
Is the use of statistics and treatment of uncertainties appropriate?
Yes
Is the presentation of the work clear?
Yes
Are the images in this manuscript (including electrophoretic gels and blots) free
from apparent manipulation?
Yes